开云app官网登录入口网页版-官方正版

#晚期卵巢癌#

59篇内容 | 2358人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2174939, encodeId=a33f21e4939de, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a> <a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a> <a href='/topic/show?id=d049108598ec' target=_blank style='color:#2F92EE;'>#同源重组修复缺陷#</a>, objectTitle=前沿进展 | PARP抑制剂获益患者高达50%！同源重组修复缺陷（HRD）检测至关重要！, objectType=article, longId=804830, objectId=824480483027, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668019396776_4754896.png, objectUrl=/article/show_article.do?id=824480483027, replyNumber=0, likeNumber=118, createdTime=2023-12-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=824480483027, moduleTitle=前沿进展 | PARP抑制剂获益患者高达50%！同源重组修复缺陷（HRD）检测至关重要！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=824480483027)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174968, encodeId=d2f821e4968d4, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a> HRD作为新兴的肿瘤分子标志物，在多种恶性肿瘤患者治疗管理中对PARP抑制剂疗效预测发挥着越来越重要的作用。《同源重组修复缺陷临床检测与应用专家共识（2021版）》指出：HRD临床检测在PARP抑制剂治疗晚期卵巢癌疗效预测中具有重要的应用价值，可对卵巢癌患者进行分层，优化相应治疗决策，最大限度扩大PARP抑制剂临床获益人群；在乳腺癌、卵巢癌、胰腺癌、前列腺癌中，其对PARP抑制剂或含铂类药物的临床应用可能也具有潜在的指导价值[1]。《卵巢癌PARP抑制剂临床应用指南（2020版）》指出：HRD检测可以使PARP抑制剂敏感人群从占20%左右的BRCA突变人群扩大到占50%左右的HRD阳性人群[2]。, objectTitle=晚期卵巢癌, objectType=topic, longId=59814, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=50, createdTime=2023-12-14, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1394589, encodeId=c085139458952, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后, objectType=article, longId=739397, objectId=5287e39397ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5287e39397ac, replyNumber=0, likeNumber=93, createdTime=2022-09-17, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5287e39397ac, moduleTitle=J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5287e39397ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394588, encodeId=2a3f13945883e, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, objectType=article, longId=739077, objectId=6949e390775b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6949e390775b, replyNumber=0, likeNumber=91, createdTime=2022-09-13, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6949e390775b, moduleTitle=ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6949e390775b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394586, encodeId=82cb1394586f8, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), objectType=article, longId=724029, objectId=ae71e2402901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae71e2402901, replyNumber=0, likeNumber=90, createdTime=2022-04-13, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae71e2402901, moduleTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae71e2402901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394587, encodeId=5af4139458e81, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, objectType=article, longId=723985, objectId=b52ce23985ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b52ce23985ec, replyNumber=0, likeNumber=71, createdTime=2022-04-12, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b52ce23985ec, moduleTitle=AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b52ce23985ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394585, encodeId=30dd1394585e9, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=87, createdTime=2022-04-04, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394584, encodeId=6dbf139458420, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=293043, objectId=5aea293043a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aea293043a4, replyNumber=0, likeNumber=69, createdTime=2021-12-30, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aea293043a4, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5aea293043a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394583, encodeId=421013945839f, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌, objectType=article, longId=220793, objectId=d997220e93d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d997220e93d1, replyNumber=0, likeNumber=69, createdTime=2021-11-23, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d997220e93d1, moduleTitle=New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d997220e93d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394582, encodeId=72141394582b6, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察, objectType=article, longId=220700, objectId=ba2d220e004b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba2d220e004b, replyNumber=0, likeNumber=73, createdTime=2021-11-22, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba2d220e004b, moduleTitle=安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ba2d220e004b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394581, encodeId=6c89139458164, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=【OC档案室】合并多种基础疾病，尼拉帕利果断启动为晚期卵巢癌伴肝功能异常患者提供持续获益, objectType=article, longId=220428, objectId=0c5922042809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c5922042809, replyNumber=0, likeNumber=71, createdTime=2021-11-17, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c5922042809, moduleTitle=【OC档案室】合并多种基础疾病，尼拉帕利果断启动为晚期卵巢癌伴肝功能异常患者提供持续获益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c5922042809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394580, encodeId=0023139458005, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, objectType=article, longId=219747, objectId=c80a219e4706, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c80a219e4706, replyNumber=0, likeNumber=0, createdTime=2021-11-05, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c80a219e4706, moduleTitle=Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c80a219e4706)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394579, encodeId=d28313945e9df, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, objectType=article, longId=211652, objectId=9a1e21165207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a1e21165207, replyNumber=0, likeNumber=103, createdTime=2021-05-23, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a1e21165207, moduleTitle=Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9a1e21165207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394578, encodeId=ad5a13945e8f7, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！, objectType=article, longId=210475, objectId=0be72104e5b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be72104e5b3, replyNumber=0, likeNumber=85, createdTime=2021-04-27, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be72104e5b3, moduleTitle=J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0be72104e5b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394577, encodeId=bb0213945e745, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, objectType=article, longId=207665, objectId=541220e665a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541220e665a5, replyNumber=0, likeNumber=93, createdTime=2021-02-28, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541220e665a5, moduleTitle=晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=541220e665a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394576, encodeId=33b313945e6e2, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=老药新用 || 来曲唑在晚期卵巢癌治疗中的作用, objectType=article, longId=206091, objectId=b24220609167, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24220609167, replyNumber=0, likeNumber=95, createdTime=2021-01-24, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24220609167, moduleTitle=老药新用 || 来曲唑在晚期卵巢癌治疗中的作用, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b24220609167)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394575, encodeId=6d6f13945e50c, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新, objectType=article, longId=206085, objectId=4a9920608543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9920608543, replyNumber=0, likeNumber=85, createdTime=2021-01-24, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9920608543, moduleTitle=2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4a9920608543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394574, encodeId=d64c13945e4ce, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=晚期卵巢癌新辅助化疗分流指南：高风险，高收益还是得不偿失？, objectType=article, longId=206082, objectId=013820608241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=013820608241, replyNumber=0, likeNumber=71, createdTime=2021-01-24, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=013820608241, moduleTitle=晚期卵巢癌新辅助化疗分流指南：高风险，高收益还是得不偿失？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=013820608241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394573, encodeId=8a2813945e327, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=Lynparza在日本获准用于治疗晚期卵巢癌、前列腺癌和胰腺癌, objectType=article, longId=205138, objectId=363b20513825, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=363b20513825, replyNumber=0, likeNumber=69, createdTime=2021-01-02, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=363b20513825, moduleTitle=Lynparza在日本获准用于治疗晚期卵巢癌、前列腺癌和胰腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=363b20513825)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1394572, encodeId=9a7013945e20d, content=<a href='/topic/show?id=2c9a5981483' target=_blank style='color:#2F92EE;'>#晚期卵巢癌#</a>, objectTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, objectType=article, longId=197518, objectId=29ba19e518a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29ba19e518a8, replyNumber=0, likeNumber=76, createdTime=2020-07-16, rootId=0, userName=siiner, userId=a3262500163, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29ba19e518a8, moduleTitle=罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=29ba19e518a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

晚期卵巢癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#晚期卵巢癌# #PARP抑制剂# #同源重组修复缺陷#

前沿进展 | PARP抑制剂获益患者高达50%！同源重组修复缺陷（HRD）检测至关重要！

2023-12-14发表于上海

yangchou (审核中...)

前往app查看评论内容

全文收起 #晚期卵巢癌# HRD作为新兴的肿瘤分子标志物，在多种恶性肿瘤患者治疗管理中对PARP抑制剂疗效预测发挥着越来越重要的作用。《同源重组修复缺陷临床检测与应用专家共识（2021版）》指出：HRD临床检测在PARP抑制剂治疗晚期卵巢癌疗效预测中具有重要的应用价值，可对卵巢癌患者进行分层，优化相应治疗决策，最大限度扩大PARP抑制剂临床获益人群；在乳腺癌、卵巢癌、胰腺癌、前列腺癌中，其对PARP抑制剂或含铂类药物的临床应用可能也具有潜在的指导价值[1]。《卵巢癌PARP抑制剂临床应用指南（2020版）》指出：HRD检测可以使PARP抑制剂敏感人群从占20%左右的BRCA突变人群扩大到占50%左右的HRD阳性人群[2]。

2023-12-14发表于浙江省

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

J Clin Oncol：奥拉帕尼维持治疗晚期卵巢癌随访长达7年的总生存预后

2022-09-17

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

ESMO 2022：奥拉帕利维持治疗新诊断BRCAm晚期卵巢癌患者7年OS结果（SOLO1/GOG-3004研究）

2022-09-13

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D)

2022-04-13

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

AACR重磅之KGOG 3046/TRU-D：度伐利尤单抗和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的II期研究

2022-04-12

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-04-04

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2021-12-30

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌

2021-11-23

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

安罗替尼治疗多线化疗后进展晚期卵巢癌的疗效观察

2021-11-22

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

【OC档案室】合并多种基础疾病，尼拉帕利果断启动为晚期卵巢癌伴肝功能异常患者提供持续获益

2021-11-17

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Lancet Oncol：SOLO1试验| 奥拉帕利维持治疗晚期卵巢癌随访5年的生存预后

2021-11-05

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Lancet Oncology：3期SOLO1试验：奥拉帕利维持治疗显著改善了晚期卵巢癌伴BRCA突变铂类化疗后患者的无进展生存期

2021-05-23

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！

2021-04-27

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

晚期卵巢癌的治疗取得新进展，GEN-1在I / II期临床中取得喜人结果！

2021-02-28

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

老药新用 || 来曲唑在晚期卵巢癌治疗中的作用

2021-01-24

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

2020年欧洲妇科肿瘤学会(ESGO)晚期卵巢癌手术质量指标更新

2021-01-24

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

晚期卵巢癌新辅助化疗分流指南：高风险，高收益还是得不偿失？

2021-01-24

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

Lynparza在日本获准用于治疗晚期卵巢癌、前列腺癌和胰腺癌

2021-01-02

siiner (审核中...)

前往app查看评论内容

#晚期卵巢癌#

罗氏的PD-L1单抗Tecentriq治疗晚期卵巢癌，III期研究失败

2020-07-16

科室
- - 订阅+
  - 更多科室
工具
服务